Dr. Reddy’s LaboratoriesThe lack of near-term catalysts given lack of details on US order pipeline and large gRevlimid hole are concerns capping performance versus peers, BofA said. The company’s transition to build more sustainable growth drivers like over-the-counter drugs and biosimilars outside the US market will be lower, but margin will remain intact.Mankind PharmaDespite earnings dilution from the Rs 13,630-crore acquisition of Bharat Serums and Vaccines Ltd., the stock has reversed…
Read More…
Source: https://www.ndtvprofit.com/markets/pharmas-nifty-beating-performance-the-key-drivers-of-the-rally